<SEC-DOCUMENT>0001140361-18-045553.txt : 20181221
<SEC-HEADER>0001140361-18-045553.hdr.sgml : 20181221
<ACCEPTANCE-DATETIME>20181221060505
ACCESSION NUMBER:		0001140361-18-045553
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181221
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181221
DATE AS OF CHANGE:		20181221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330336973
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		181247499

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>8-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 5.1.0.0
         Copyright 1995 - 2018 Broadridge -->
  </head>
<body text="#000000" bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">Washington, D.C.&#160; 20549</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center; font-size: 18pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">FORM 8-K</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">CURRENT REPORT</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Date of report (Date of earliest event reported):&#160; December 21, 2018</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: center; font-size: 24pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(Exact Name of Registrant as Specified in Charter)</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Delaware</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(State or Other Jurisdiction of Incorporation)</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse;" id="zcaa19d873c7845c9b43c24c3d89c3241">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">000-19125</font></div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">33-0336973</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(Commission File No.)</font></div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(IRS Employer Identification No.)</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2855 Gazelle Court</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Carlsbad, CA 92010</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(Address of Principal Executive Offices and Zip Code)</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div>
        <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Registrant&#8217;s telephone number, including area code: <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(760) 931-9200</font></font></div>
        <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
            </font></font></div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
          following provisions:</font></div>
      <div style="text-align: left;">
        <div><br>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="z62c3b0e161024e9fb352b9037f3a7811">

              <tr>
                <td style="width: 18pt; vertical-align: top;">&#9744;</td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: left; text-indent: -36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="zf18459ea0c854f66a2a18ea4c2bd6787">

              <tr>
                <td style="width: 18pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#9744;</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: left; text-indent: -36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="z42e88bd0dece46ceac23d617ad6ea293">

              <tr>
                <td style="width: 18pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#9744;</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: left; text-indent: -36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="z70afa68bcee64373895ce258025c3d69">

              <tr>
                <td style="width: 18pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#9744;</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this
          chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Emerging growth company</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times
            New Roman';">&#9744;</font></font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
          </font></font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
          or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">&#9744;</font></font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
          </font></font></div>
      <div style="text-align: justify;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-size:
          10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font></font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="za736b9f44c344af1998dfd8562a96460">

              <tr>
                <td style="width: 63pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Item 5.02</font></td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
        </div>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">On December 20, 2018, Ionis Pharmaceuticals, Inc. (the &#8220;Company&#8221;) announced that, effective January 2020, the Company&#8217;s founder and chief executive officer,
          Stanley T. Crooke, M.D., Ph.D., will transition from chief executive officer to executive chairman of the Company&#8217;s board of directors (the &#8220;Board&#8221;).&#160; Dr. Crooke will remain active in the Company, providing strategic advice and participating in
          the Company&#8217;s scientific activities.&#160; The Board has selected Brett P. Monia, Ph.D., Ionis&#8217; chief operating officer and a founder of the Company, to serve as chief executive officer beginning in January 2020.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">A copy of the press release announcing this transition plan is included with this report as exhibit 99.1 and incorporated herein by reference.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="zcecdbf924b1147cd8973262254e093dc">

              <tr>
                <td style="width: 63pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Item 9.01.</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits.</font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z2f76d576c8be4130a1846b42628a1f9d" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Exhibits.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="zb8d6f0c8863e4340902f3fcc830c5274">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;"><a href="ex99_1.htm"><font style="font-size: 10pt; font-family: 'Times New
                      Roman';">99.1</font></a></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';">Press Release dated December 20, 2018.</font></div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">SIGNATURE</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be
          signed on its behalf by the undersigned, thereunto duly authorized.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse;" id="z27caacdb5f0f400a8cabf17d1df2e0b0">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;"><br>
              </div>
            </td>
            <td colspan="2" style="width: 3%; vertical-align: top;" rowspan="1">
              <div style="text-align: justify;">
                <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Ionis Pharmaceuticals, Inc.</font></div>
              </div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="1" rowspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Dated:&#160; December 21, 2018</font></div>
            </td>
            <td colspan="1" style="width: 3%; vertical-align: top; padding-bottom: 2px;"><font style="font-size: 10pt; font-family: 'Times New Roman';">By:</font></td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">/s/ Patrick R. O&#8217;Neil</font></font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;"><br>
              </div>
            </td>
            <td colspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Patrick R. O&#8217;Neil</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;"><br>
              </div>
            </td>
            <td colspan="1" style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Senior Vice President, Legal, General Counsel and Chief Compliance Officer</font></div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 5.1.0.0
         Copyright 1995 - 2018 Broadridge -->
  </head>
<body text="#000000" bgcolor="#ffffff" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
      </div>
      <div style="text-align: right;"><font style="font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold;"> <img src="image00001.jpg"></div>
      <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Announces Plans for Management Transitions in 2020</div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Carlsbad, Calif., December 20, 2018</font> &#8211; Ionis Pharmaceuticals, Inc.
          (NASDAQ: IONS) and its Board of Directors announced today that, effective January 2020, Ionis&#8217; founder and CEO, Stanley T. Crooke, M.D., Ph.D., will be transitioning from chief executive officer to executive chairman of Ionis&#8217; board of directors.
          As executive chairman, Dr. Crooke will continue to be responsible for the activities of the board and will remain active in the company<font style="font-size: 10pt; font-family: 'Times New Roman';">,</font> providing strategic advice and
          continuing to participate in the scientific activities of the company. The board has selected Brett P. Monia, Ph.D., who has been Ionis&#8217; chief operating officer for the last year and a member of the Ionis team since its founding nearly 30 years
          ago, to serve as Ionis&#8217; chief executive officer starting in January 2020.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Dr. Crooke said of this planned transition, &#8220;I am very pleased with the state of Ionis today and I believe that in January 2020<font style="font-size: 10pt;
            font-family: 'Times New Roman';">,</font> when the transition will be effected, the company will be even stronger<font style="font-size: 10pt; font-family: 'Times New Roman';">.</font> The Board and I are confident that implementing this
          transition in 2020 provides the optimum timing to ensure a smooth transition and provide successful long-term leadership for the company. We are equally confident that we have the right person to lead Ionis moving forward. Brett is a founding
          member of Ionis, an outstanding scientist and a well-recognized expert in antisense technology. He is a business leader in biopharma with broad experience in multiple aspects of the industry. As an executive officer at Ionis for the past seven
          years, Brett contributes to all strategic decisions.&#8221;</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Dr. Monia stated, &#8220;I am excited about the opportunity to advance Ionis to the next chapter in its evolution. The company&#8217;s future has never been brighter.
          With the new medicines in our pipeline, we are offering more hope to more patients with devastating diseases with inadequate or no treatment options. I am committed to ensuring that Ionis continues to advance these important medicines and our
          antisense platform, while continuing to build on the company&#8217;s financial strength, so that we can continue to provide great benefit to even more patients and to our shareholders. I am grateful to Stan for his remarkable vision, creativity and
          passion in leading Ionis since its founding almost 30 years ago.&#8221;</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Dr. Crooke founded Ionis Pharmaceuticals to pursue the development of a new drug discovery technology&#8212;antisense. Since that time the company has made
          significant advancements in antisense technology. During his tenure at Ionis, he has led the scientific development of a new platform for drug discovery, antisense technology<font style="font-size: 10pt; font-family: 'Times New Roman';">,</font>
          and engineered the creation of one of the largest and most advanced development pipelines in the biotechnology industry<font style="font-size: 10pt; font-family: 'Times New Roman';">.</font> Today, Ionis is a multi-product company and the leader
          in RNA-targeted therapies, having developed breakthrough medicines, such as SPINRAZA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and TEGSEDI&#8482;<font style="font-size: 10pt; font-family: 'Times New Roman';">,</font> for patients with rare genetic diseases, and has a pipeline of
          over 45 medicines in development or on the market for treating patients with a broad range of diseases&#8212;from rare to common ones.</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left;">
        <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold;"> <img src="image00001.jpg">
          <div><br>
          </div>
        </div>
        <font style="font-size: 10pt; font-family: 'Times New Roman';">Dr. Crooke has been recognized throughout his career as a leader in the field. He has published nearly 500 scientific publications, edited more than 20 books, and has numerous patents.
          He was named Man of the Year by The Crohn&#8217;s Disease Society; he received the SMA Breakthrough Award and he achieved the Lifetime Achievement Award from Scrip. He received the 2016 Oligonucleotide Therapeutic Society Lifetime Achievement Award and
          the E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances presented by The American Chemical Society. Dr. Crooke was named by Nature Biotechnology as one of the most influential individuals in biotechnology and has
          received the Director of the Year Award from the Corporate Directors Forum, the Distinguished Scientist Award from the American Chemical Society (San Diego Chapter), the Helix Award, for the most important innovation in biotechnology by the
          Biotechnology Industry Organization, BIO, Stony Brook University and the Center for Biotechnology, and the Ernst and Young and Entrepreneur Award of the Year Award as well as Distinguished Alumnus at Baylor College of Medicine and at Butler
          University.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Dr. Monia is a founding member of Ionis. He has been an executive officer of the company since the beginning of 2012 and the chief operating officer since
          the beginning of 2018. He has served as the senior vice president of translational medicine and as the franchise leader for programs in oncology and rare diseases at Ionis. As the former head of drug discovery at Ionis, Dr. Monia was responsible
          for establishing strategic directions for preclinical drug discovery research focused on RNA-directed therapeutic platforms, establishing and supervising of early clinical development strategies, and coordinating research activities with clinical
          investigators, consultants, and with corporate partners. Dr. Monia has authored more than 200 primary scientific publications. His contributions include research into the medicinal chemistry and mechanisms of action of oligonucleotide-based drugs
          in cell culture and in animals, and in the establishment of numerous preclinical and clinical programs, many of which have resulted in clinical proof of concept across a broad range of therapeutic areas, including oncology, cardiometabolic
          diseases, inflammation, respiratory diseases, neurodegenerative diseases and rare diseases. Programs under Dr. Monia&#8217;s direct supervision have resulted in the clinical development of more than 40 antisense-based drugs to date, resulting in
          multiple market authorization approvals. Dr. Monia has also served as President of the Oligonucleotide Therapeutics Society (OTS), and currently serves on the Board of Directors for Dynacure Therapeutics and as an adjunct professor of Biology at
          San Diego State University.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">About Ionis Pharmaceuticals, Inc.</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform
          with the potential to treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs &#8211; such as children
          and adults with spinal muscular atrophy (SMA). We created SPINRAZA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (nusinersen)* and are proud to have brought new hope to the SMA community by developing the first and only approved treatment for this disease.</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: left;">
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 drugs with the potential to treat patients with cardiovascular
            disease, rare diseases, neurological diseases, infectious diseases and cancer. We created TEGSEDI&#8482; (inotersen) the world&#8217;s first RNA-targeted therapeutic approved for the treatment of polyneuropathy of hereditary transthyretin (TTR) amyloidosis
            (ATTR) in adult patients that our affiliate Akcea Therapeutics is commercializing. Together with Akcea, we are also bringing new medicines to patients with cardiometabolic lipid disorders.</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">To learn more about Ionis follow us on twitter @ionispharma or visit </font><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>http://ir.ionispharma.com/</u></font><font style="font-size: 10pt; font-family: 'Times New Roman';">.</font></font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">*Spinraza is marketed by Biogen.</font></div>
        <font style="font-size: 10pt; font-family: 'Times New Roman';"> </font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left;">
        <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold;"> <img src="image00001.jpg">
          <div><br>
          </div>
        </div>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Ionis&#8217; Forward-looking Statement</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">This press release includes forward-looking statements regarding Ionis Pharmaceuticals' business and the therapeutic and commercial potential of Ionis'
          technologies, products in development and commercial products, including SPINRAZA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and TEGSEDI&#8482; (inotersen). Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a
          forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe
          and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to
          differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently
          known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December
          31, 2017, and most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of this and other documents are available from the Company.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">In this press release, unless the context requires otherwise, &#8220;Ionis,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refers to Ionis Pharmaceuticals and its
          subsidiaries.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Ionis Pharmaceuticals<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup> is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup> is a trademark of Akcea Therapeutics, Inc.
          TEGSEDI<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup> is a trademark of Akcea Therapeutics, Inc.<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</font>SPINRAZA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a registered trademark of Biogen.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Ionis Pharmaceuticals Investor Contact:</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">D. Wade Walke, Ph.D.</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Vice President, Investor Relations</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">760-603-2741</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: left;">
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Ionis Pharmaceuticals Media Contact:</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Roslyn Patterson</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Vice President, Corporate Communications</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">760-603-2681</font></div>
        <font style="font-size: 10pt; font-family: 'Times New Roman';"> </font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <font style="font-size: 10pt; font-family: 'Times New Roman';"> </font>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">###</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <font style="font-size: 10pt; font-family: 'Times New Roman';"></font>
      <div style="text-align: center;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="font-size: 10pt; font-family: 'Times New Roman';
          font-weight: bold;"> </font></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !( 18# 2(  A$! Q$!_\0
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MDC.0/8UO:?=PW]C!=VK;X)T$D;8QE2,@XKY]_:"_Y'6#_KR3_P!":O;? O\
MR)>A_P#7E#_Z *;6EQ)ZFU(ZQQL[G"J"Q/L*Y;1/'_AW6]3BT_3;YI;J7.Q#
M"ZYP"3R1CH*Z/4?^0?<_]<F_D:^:/@S_ ,E&TOZ2_P#HMJ$K@W8^GZ**\O\
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MX2XC>)E1C_>0D<J?TZ4JU"5/WF51KQJ>Z=E1117.= 4444 ?.G[0'_([Q?\
M7FG_ *$U>W^!O^1-T3_KSB_]!%>(?M ?\CO%_P!>:?\ H35[?X&_Y$W1/^O.
M+_T$53V1*W8WQYJ+:3X.U>\C.)([=@A]&/ _4BO#O@3I":CXT^TSJ&2PA,P!
M_OD[5_F3^%>N?&)6;X<ZOM[*A/TWK7G_ .SBRC4M;4_?,41'TRV?YBA; ]SW
M.BBBI*/G#X[Z0FG>,Q=0J%2_A$S8_O@[6_H?QKW'P'J+:KX.TB]D.9)+=0Y]
M6'RG]0:\J_:.9?[0T-?XQ%*3],K7H'P=5E^'&C[NZR$?3S&JGL2MS;\9?\BC
MK7_7E-_Z :\$^"MC;ZMK6K:7>+N@O-.>-AZ?,N"/<'FO>_&7_(HZU_UY3?\
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M&Q\Z?M ?\CO%_P!>:?\ H35[?X&_Y$W1/^O.+_T$5X?^T 0/'$63_P N:?\
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M^UMY!AG;L[#L!V'K7N5$GT"*ZF/XR_Y%'6O^O*;_ - ->$_ '_D>F_Z\I/\
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MQ'!I.G27%NP$T8&XQDC(#+GC((-8?PN2]T#6-4\.WVE_V9:R*M_I\*SB953
M25=X &=X#8_VS2Z;XDTG0/B!XQBU>[%K)<W%JT0=&.\?9T&00,=>*;CJTA*>
MB;.TNKG1?"^F^9<R6.E6((4%BL2;CT Z9-6],U&SU6SCN]-NH;NUD^Y+"X=6
M]>17'?$_[+#+H-]=7LVFR6MR[0WQM1<6\+&,@B93T!!(#<8/<5-\*[QK[2M3
ME,%KY9OY-EY:V[01WPVKF8(Q.,G*DYP2N12Y?=N/F]ZQVM%%%06%%%% #717
M0JZAE(P01D&N-\1?"_P9X@W-J&@68E;K+;KY+_7*8S^-%%-2<=F)Q3W,C3?@
MCX)L@-VGSW6WIY]RY_0$5T^G>!O"VFX^Q^']-0CHQMU8_F<FBBJ=23W9*IP6
MR.A@AC@C$<$:1QCHJ*% _ 4^BBH+"BBB@ HHHH **** "C%%% "8I<444 &*
M,444 &*,444 &****  C/:BBB@ HQ110 F*7%%% !BC%%% !BC%%% !1110!
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
